Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm studyJames R. Berenson, Regina A. Swift, Edward A. Stadtmauer et al.|British Journal of Haematology|2006Cited by 83
A Phase I/II Trial Evaluating the Combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for Patients with Relapsed or Refractory Multiple Myeloma.James R. Berenson, Sal Bevivino, Regina A. Swift et al.|Blood|2005Cited by 11